TECHNOLOGY FEATURES AND SPECIFICATIONS PER TEST

		Liquid biopsy	Somatic tumor profile		Hereditary cancer	
		NeoThetis	ForeSENTIA	Detect&Act	PreSENTIA	Predict& Prevent
Actionability	Available therapies	•	•	•		
	Approved treatments	•	•	•		
	Referral to clinical trials	•	•	•		
	Medical management recommendations	•	•	•	•	•
Technical features and markers analysed	Technology	Target capture enrichment technology via NGS	Target capture enrichment technology via NGS	Exome-based technology via NGS	Target capture enrichment technology via NGS	Exome-based technology via NGS
	TMB	o	o	o		
	MSI	o	o	o		
	SNVs/INDELs	•	•	•	•	•
	CNAs	•	o	•	•	•
	Rearrangements	•	o	o		
	Other biomarkers *Biological molecule that is a sign of a normal or abnormal process, or of a disease*	o	o	o		
	Histopathology		Upon request	o		
	Full exonic coverage *Exceptions apply*	o	o	o	•	•
	Reported variants	•	•	•	•	•
	Variants of unknown clinical significance (VUS) reported	Tier I/II	Tier I/II	Tier I/II	Pathogenic/Likely pathogenic	Pathogenic/Likely pathogenic
	Target selected intronic regions of clinical importance	•	•	•	•	•
	Target splice junction	•	•	•	•	•
Other test details	Turnaround time (TAT)	6-9 days	10-15 days	7-20 days	10-15 days	15-25 days
	Sample type	Blood Sample	FFPE	FFPE	Buccal Swab	Buccal Swab

• Included o Panel applicable

ABOUT MEDICOVER GENETICS

Medicover Genetics is a leading healthcare company specialising in genetic medicine, with more than 25 years of experience in genetics diagnostics. Medicover Genetics offers genetic testing services and genetic counselling, proprietary CE-IVD marked solutions and a versatile Technology Transfer Platform which enables partners to perform high fidelity genetic tests in-house. With services in over 30 countries across Europe, Asia, and Africa, the company empowers laboratories, healthcare professionals and patients to place genetics at the core of medical decisions. Committed to enhancing health and well-being, Medicover Genetics provides meaningful, actionable diagnostic solutions, improving disease prognosis, clinical management, and therapy selection for genetic disorders. The CAP-accredited, CLIA-, GMP- and ISO9001, 15189, and 13485 certified laboratories ensure the highest quality standards. www.medicover-genetics.com

Medicover Genetics is part of Medicover, a leading international healthcare and diagnostic services company founded in 1995 and listed on Nasdaq Stockholm. www.medicover.com

PURPOSE
To empower people to use comprehensive and meaningful genetic tests at the forefront of their diagnostic journey

MISSION
Leverage advancements in genomics to develop relevant diagnostic solutions, supported by professional medical interpretation, to improve people's health and well-being

VISION
To place genetics at the core of medical decisions

VALUES
Humanity • Passion • Medical Excellence • Innovation • Integrity

- Leader in genetic testing with >25 years of experience in counselling and diagnostics
- Provider of turn-key solutions through CE IVD Kits and Technology Transfer Platform for laboratories of any size
- Experienced clinical team providing medically-validated reports and genetic counselling
- Combined with histopathology and clinical laboratory testing
- CAP- accredited and CLIA-, GMP- and ISO9001, 15189 and 13485 certified

HOW TO ORDER

- Order the test you are interested in by getting in touch with us
- Receive the test kit
- Collect the applicable sample material from the patient and send the sample to us
- We will analyze the sample in our accredited laboratories
- We will report the results directly to you

For Hereditary cancer TarCET IVD kits, please visit our website.

CONTACT US

info.genetics@medicover.com

Germany
Teltowkanalstr. 1b, 12247 Berlin

Cyprus
Neas Engomis 31, 2409 Nicosia

MEDICOVER GENETICS

MKT-MGCG-GEN-ONPT-EN-V02

MEDICOVER GENETICS

PLACING GENETICS AT THE CORE OF MEDICAL DECISIONS

Oncology Portfolio

www.medicover-genetics.com

Medicover Genetics oncology portfolio offers a wide range of tests that empower healthcare providers to identify the best solution for their patients. Our expertise in oncology and unique technology enables the development of highly accurate tests including hereditary cancer, tumor profiling and liquid biopsy tests that can maximize the possibilities of successful treatment, identify prophylactic measures for effective preventative actions, and improve prognosis.

LIQUID BIOPSY

A non-invasive blood test that identifies the genetic characteristics of primary and metastatic tumors. It guides therapy selection and re-evaluation for therapy resistance, and offers novel immunotherapy options for treatment.

BENEFITS OF LIQUID BIOPSY

- Non-invasive and safe for patients
- Identifies tumor heterogeneity of primary tumors and metastatic lesions
- Easily repeatable and convenient for the patient
- Available for patients who are not eligible or unfit for another tumor biopsy
- Enables evaluation of tumor genetic profile for therapy selection at frequent intervals (during disease progression or therapy resistance)

NeoThetis

Blood sample

6-9 days

EXTENDED TESTS

- Pan-Cancer Plus — *222 genes, analysis of MSI and bTMB*
- Pan-Cancer — *80 genes, analysis of MSI*

CANCER-SPECIFIC TESTS

- NeoThetis Breast/Gynecological — *48 genes*
- NeoThetis Colorectal — *34 genes*
- NeoThetis Gastric — *23 genes*
- NeoThetis Melanoma — *28 genes*
- NeoThetis NSCLC — *36 genes*
- NeoThetis Pancreatic — *26 genes*
- NeoThetis Prostate — *35 genes*

SOMATIC TUMOR PROFILE

Tests that identify the genetic and molecular characteristics of tumors by analysing tissue samples from tumor biopsy. They guide precise therapy selection, enabling for novel immunotherapy options.

BENEFITS OF SOMATIC TUMOR PROFILE

- Deep analysis of tumor molecular characteristics
- Identifies tumor heterogeneity, based on the biopsied area
- Identifies the genetic alterations and immunotherapy biomarkers involved in cancer development and resistance
- Guides precision medicine and personalised treatment options depending on the type of tumor
- Improves the clinical management and disease classification

ForeSENTIA

FFPE tissue sample from a biopsy

10-15 days

EXTENDED TESTS

- Pan-Cancer Plus — *(222 genes, analysis of MSI and TMB)*
- Pan-Cancer — *(80 genes, analysis of MSI)*

CANCER-SPECIFIC TESTS

- Breast/Gynecological — *48 genes*
- Colorectal — *34 genes*
- Lung (NSCLC) — *36 genes*
- Prostate — *36 genes*
- Melanoma — *22 genes*
- Glioma — *22 genes*

GENE-FOCUSED TESTS

- BRAF
- EGFR
- IDH1 & IDH2
- KRAS & NRAS
- PIK3CA & AKT1

Histology available upon request

Detect&Act

FFPE tissue sample from a biopsy

Histopathology analysis: 7-10 days
Genetic analysis: 7-20 days

TARGETED-THERAPY TESTS

• Bladder • Breast • Colon • Gastric • GIST • Melanoma • NSCLC • Ovarian • Pancreatic • Prostate

COMPREHENSIVE TEST

>500 genes, analysis of MSI and TMB

GENE PANELS

- Bladder — *28 genes*
- Breast — *23 genes*
- Colon — *25 genes*
- Gastric — *23 genes*
- Gastrointestinal stromal — *22 genes*
- Glioblastoma — *15 genes*
- Melanoma — *19 genes*
- NSCLC — *14 genes*
- Ovarian — *17 genes*
- Panceratic — *27 genes*
- Prostate — *28 genes*
- Thyroid — *7 genes*

HEREDITARY CANCER

Tests that identify the genetic changes that increase the risk of developing hereditary cancer, and if a patient's cancer is caused by an inherited germline mutation.

BENEFITS OF HEREDITARY CANCER TESTING

- Non-invasive and safe for patients
- Identifies germline mutations that increase the risk of developing cancer, or hereditary cancer predisposing syndromes
- Improves the clinical management of the patients, and their family and informs other family members of their risk
- Improves disease classification
- Helps in identifying prophylactic measures for cancer prevention, if applicable

PreSENTIA

Buccal swab

10-15 days

PreSENTIA TESTS

- Pan-Cancer — *62 genes*
- Breast/gynecological — *26 genes*
- Breast/gynecological guidelines-based — *19 genes*
- Breast high-risk — *7 genes*
- BRCA1/BRCA2 — *2 genes*
- Colorectal — *17 genes*
- Colorectal high-risk — *10 genes*
- Colorectal non-polyposis syndrome — *5 genes*
- Colorectal polyposis syndrome — *7 genes*
- Myelodysplastic syndrome/Leukemia — *24 genes*
- Gastric — *14 genes*
- Prostate — *15 genes*
- Pancreatic — *17 genes*
- Renal — *13 genes*
- Skin (XP-associate) — *9 genes*
- Familial melanoma — *7 genes*
- Paraganglioma/pheochromocytoma — *6 genes*
- Parathyroid — *1 gene*
- Thyroid — *1 gene*

Predict&Prevent

EDTA Blood or Buccal swab

15-25 days

PREDICT&PREVENT TESTS

- Comprehensive hereditary cancer panel — *54 genes*
- Colon cancer extended panel — *21 genes*
- Colon cancer core panel — *16 genes*
- Breast and ovarian cancer extended panel — *27 genes*
- Breast and ovarian core panel — *19 genes*
- Breast and ovarian BRCA1, BRCA2 — *2 genes*
- Endocrine tumors — *14 genes*
- Fanconi anemia — *22 genes*
- Gastrointestinal tumors — *20 genes*
- Kidney cancers — *13 genes*
- Nervous system/ Brain tumors — *14 genes*
- Pancreatic tumors — *15 genes*
- Prostate cancer — *11 genes*
- Skin tumor — *14 genes*
- Unspecific tumor syndromes — *7 genes*

UNIQUE FEATURES

Immunotherapy eligibility:
Immunotherapy biomarkers, such as TMB and MSI, are assessed. FDA/EMA approved immunotherapy options can be available depending on the type of tumor.

Tumor Mutational Burden (TMB):
TMB is an independent, tumor agnostic biomarker. It measures the total number of mutations per megabase and identifies patients eligible for specific immunotherapy treatment.
Blood TMB (**bTMB**), is an emerging biomarker that is analysed from the circulating tumor DNA released in the blood from tumors.

ForeSENTIA, Detect&Act, NeoThetis

Microsatellite Instability (MSI):
Identifies mutation frequency within satellites (short, repeated DNA sequences of DNA). It can have therapeutic and prognostic value for patients with solid tumors who present high MSI status.

ForeSENTIA, Detect&Act, NeoThetis

Eligibility on clinical trials:
Tested genes and genomic signatures serve as selection criteria in ongoing clinical trials.

ForeSENTIA, Detect&Act, NeoThetis

Clinically relevant genes:
The genetic alterations tested are included in clinical practice guidelines and are recommended by professional bodies such as NCCN, ESMO and ASCO.

ForeSENTIA, Detect&Act, NeoThetis, PreSENTIA, Predict&Prevent

Technological advantages:
The tests are based on technology platforms validated for their precision and accuracy.

ForeSENTIA, Detect&Act, NeoThetis, PreSENTIA, Predict&Prevent

Clinical interpretation of results:
Detailed interpretation of the results on the report, guiding the healthcare providers to identify the best solutions for their patients.

ForeSENTIA, Detect&Act, NeoThetis, PreSENTIA, Predict&Prevent